Journal Article

Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States

Cai, Zhaohui, Eslava, Sergio, Siegel, Corey A., Yang, Fei

2020

Overview

Biologic therapies have been available for inflammatory bowel disease for >20 years, but patient outcomes have not changed appreciably over this time period. To better understand medication utilization for this disease, we evaluated a novel technique for visualizing treatment pathways, including initial treatment, switching, and combination therapies. This retrospective, observational study used administrative claims data from the Truven Health MarketScan Commercial and Medicare Database. Adult patients with ≥2 consecutive health claims and newly diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) were evaluated. Treatment pathways were visualized using Sankey diagrams representing the number of patients receiving treatment and duration of each treatment. In all, 28,119 patients with UC and 16,260 patients with CD were identified. The most common initial treatment for UC was 5-aminosalicylic acid monotherapy (61% of the patients), followed by corticosteroid monotherapy (25%); <1% of patients were initially treated with biologics. The most common initial treatment for CD was corticosteroid monotherapy (42%), followed by 5-aminosalicylic acid monotherapy (35%); <5% of the patients were initially treated with biologics. Significantly fewer patients followed biologic vs nonbiologic treatment pathways (UC: 6% vs 94%, CD: 19% vs 81%, both P < 0.05). Significantly fewer patients with inflammatory bowel disease followed treatment pathways that included biologic therapies compared with nonbiologic therapies, and very few patients were ever initiated on biologic therapy. Although we have made significant progress in treatment, our most effective medications are only being used in a small proportion of patients, suggesting barriers prevent optimized patient management.

• Publisher: Wolters Kluwer,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subject: Administrative Claims, Healthcare - statistics & numerical data / Age / Biological products / Biological Products - therapeutic use / Colitis, Ulcerative - drug therapy / Colitis, Ulcerative - immunology / Critical Pathways - statistics & numerical data / Crohn Disease - drug therapy / Crohn Disease - immunology / Crohn's disease / Drug Therapy, Combination - methods / Drug Therapy, Combination - statistics & numerical data / Drug Utilization - statistics & numerical data / Female / Follow-Up Studies / Geography / Glucocorticoids - therapeutic use / Health care policy / Humans / Immunomodulators / Immunosuppressive Agents - therapeutic use / Induction Chemotherapy - methods / Induction Chemotherapy - statistics & numerical data / Inflammatory bowel disease / Maintenance Chemotherapy - methods / Maintenance Chemotherapy - statistics & numerical data / Male / Medicare / Mesalamine - therapeutic use / Middle Aged / Patients / Retrospective Studies / Treatment Outcome / United States